Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00041314 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 2
Development phase
20
Study locations

NCT00041314: Completed Phase 2 study of Lung Cancer, sponsored by Eastern Cooperative Oncology Group.

NCT00041314 is a Phase 2 study of Lung Cancer that has completed, run by Eastern Cooperative Oncology Group. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00041314, a Phase 2 study of Lung Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin, gemcitabine, and exisulind in treating patients who have advanced non-small cell lung cancer.

Conditions Studied

Lung Cancer

Interventions

  • DRUG carboplatin
  • DRUG gemcitabine hydrochloride
  • DRUG exisulind

Study Locations (20)

Illinois

  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
  • Veterans Affairs Medical Center - Lakeside Chicago - Chicago
  • CCOP - Central Illinois - Decatur
  • CCOP - Evanston - Evanston
  • Evanston Northwestern Health Care - Evanston
  • CCOP - Illinois Oncology Research Association - Peoria

Florida

  • Veterans Affairs Medical Center - Gainesville - Gainesville
  • Veterans Affairs Medical Center - Miami - Miami
  • H. Lee Moffitt Cancer Center and Research Institute - Tampa
  • Veterans Affairs Medical Center - Tampa (Haley) - Tampa

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • Veterans Affairs Medical Center - Palo Alto - Palo Alto
  • Stanford University Medical Center - Stanford

Georgia

  • Emory University Hospital - Atlanta - Atlanta
  • Veterans Affairs Medical Center - Atlanta (Decatur) - Decatur

Alabama

  • University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham

Arizona

  • CCOP - Scottsdale Oncology Program - Scottsdale

Colorado

  • CCOP - Colorado Cancer Research Program, Inc. - Denver

Delaware

  • CCOP - Christiana Care Health Services - Wilmington

Trial Details

FieldValue
Start Date 2002-10-04
Est. Completion 2007-06-15
Phase Phase 2

Sponsor

Eastern Cooperative Oncology Group

141 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00041314

The ClinicalTrials.gov registry entry for NCT00041314 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which carboplatin is the first listed.

NCT00041314 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Illinois, Florida, California.

Frequently Asked Questions

What is clinical trial NCT00041314 about?

NCT00041314 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin, gemcitabine, and exisulind in treating patients who have...

What is the current status of trial NCT00041314?

This trial is currently completed. It is a Phase 2 study. The study started on 2002-10-04. Estimated completion is 2007-06-15.

What conditions does trial NCT00041314 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00041314?

The interventions under investigation include: carboplatin (DRUG), gemcitabine hydrochloride (DRUG), exisulind (DRUG).

Who is sponsoring clinical trial NCT00041314?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00041314 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.